Filing Flows › Materials › Balchem (BCPC)
Balchem (BCPC) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 23, 2026 · Balchem (BCPC) Q3 2026 earnings results →
Q3 2026 Revenue up 9% year over year to $291M · 16¢ of every $1 of revenue kept as net profit · operating margin 21.5%
Balchem made $291M in Q3 2026 (+9% Y/Y): Product Sales Revenue $290M, Royalty Revenue $401K. Operating margin 21.5%, net earnings $46.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 23, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $290.7M in Q3 2026, up 9% year over year and up 2% from the previous quarter. Product Sales Revenue was the largest line at 100% of revenue. Product Sales Revenue added $23.2M year over year (up 9%), 100% of the total change. Royalty Revenue declined 16%.
Gross margin was 36.4%, up 0.7 points from Q3 2025. Operating profit was $62.4M, a 21.5% margin (up 1.1 points year over year). Of the extra revenue versus Q3 2025, 34% reached operating profit, above the 20% margin then. Operating expenses grew 6% against revenue growth of 9%. The fastest-growing cost line was Research & development (+19%). Net earnings were $46.7M, up 16% year over year. The effective tax rate was 22.2%.
Operating cash flow was $69.8M (up 6% year over year), 149% of net earnings. Non-cash charges added back $12.4M of depreciation and amortization and $5.0M of share-based compensation. Working capital and other items added $5.6M. After capital expenditures and proceeds from the sale of assets ($11.9M), free cash flow as the company reports it was $57.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 23, 2026 | $291M | +9% | 21.5% | $46.7M | $69.8M |
| Q2 2026 | 10-Q | Jul 31, 2026 | $284M | +11% | 20.9% | $44.6M | $46.7M |
| Q1 2026 | 10-Q | Apr 30, 2026 | $271M | +8% | 20.5% | $40.3M | $40.1M |
| Q4 2025 | 10-K | Feb 20, 2026 | $264M | +10% | 19.8% | $39.2M | $67.3M |
| Q3 2025 | 10-Q | Oct 21, 2025 | $268M | +12% | 20.4% | $40.3M | $65.6M |
| Q2 2025 | 10-Q | Jul 31, 2025 | $255M | +9% | 20.1% | $38.3M | $47.3M |
| Q1 2025 | 10-Q | Apr 24, 2025 | $251M | +4% | 20.4% | $37.1M | $36.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Balchem
Balchem Corporation (“Balchem,” the “Company,” “we” or “us”), was incorporated in the State of Maryland in 1967. We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
In its own words, from its 10-K, filed Feb 20, 2026.
Balchem against its Chemicals & Allied Products peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +9% against the peers' median +9%. Operating margin: 21.5% against the peers' median 9.5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BCPC Balchem | Q3 2026 | $291M | +9% | 21.5% |
| OLN Olin | Q3 2026 | $1.7B | +2% | 3.4% |
| HUN Huntsman | Q3 2026 | $1.7B | +18% | 2.3% |
| Huntsman International LLC | Q2 2026 | $1.7B | +14% | 2.2% |
| CC Chemours | Q3 2026 | $1.5B | +3% | 14.4% |
| SOLS Solstice Advanced Materials | Q3 2026 | $1.0B | +8% | 10.7% |
| IOSP Innospec | Q3 2026 | $474M | +7% | 8.8% |
| PRM Perimeter Group | Q3 2026 | $390M | +24% | 106.8% |
| ECVT Ecovyst | Q3 2026 | $309M | +51% | 9.5% |
Source: Balchem 10-Q on SEC EDGAR · CIK 9326 · Chemicals & Allied Products
13F: who owns BCPC and who is buying
More on BCPC
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results